Anaerotruncus Colihominis/Massiliensis Test

Anaerotruncus colihominis and related species are anaerobic bacteria that live in the large intestine and produce butyrate, a short-chain fatty acid that fuels colon cells, supports the gut barrier, and serves as a key anti-inflammatory signaling molecule. Butyrate is also known to act as a histone deacetylase (HDAC) inhibitor, which means it can influence gene expression by modifying how tightly DNA is packaged. These combined actions place Anaerotruncus spp. at an interesting intersection of gut health, immunity, metabolism, and potentially even brain function.

Their most studied role is immune regulation. In mouse models of multiple sclerosis, adding A. colihominis reduced disease severity by increasing a population of regulatory T cells known as RORγt-positive Tregs. Regulatory T cells are immune cells that help keep inflammation in check, and these particular Tregs release interleukin-10, an anti-inflammatory cytokine. Although people with multiple sclerosis tend to have higher levels of A. colihominis in their stool, this may reflect a compensatory response rather than a harmful one: the body may be trying to counteract ongoing inflammation by expanding butyrate-producing bacteria.

Anaerotruncus may also play a role in cancer biology, particularly in the liver. Studies show that people with intrahepatic metastatic hepatocellular carcinoma often have significantly reduced levels of A. colihominis. In experimental models, restoring a more balanced gut community that includes Anaerotruncus reduced tumor spread within the liver. These findings point toward the immune-calming and barrier-protective effects of butyrate as a possible mechanism.

Metabolically, less is known about Anaerotruncus massiliensis specifically, but related butyrate producers influence glucose regulation and inflammation through their HDAC-inhibiting effects. This connection raises the possibility that Anaerotruncus species may also shape metabolic and epigenetic pathways that matter for healthy aging, though more research is needed.

Overall, Anaerotruncus species appear to be beneficial members of the gut community. Higher levels seem to coincide with more effective immune regulation and lower cancer risk, while depletion is associated with inflammation and disease progression. Their emerging roles in neuroinflammation, liver cancer, and epigenetic signaling make them a compelling target for future therapeutic strategies, including dietary approaches and microbiome-directed interventions.